Citron's Left Said to Take New Short Stake in Valeant Pharma (VRX); Says Worth $0

(Updated - July 13, 2016 12:52 PM EDT)

Citron's Andrew Left said to take a new short stake in Valeant Pharma (NYSE: VRX).

UPDATE - According to RealMoney, Left is calling Valeant a zero.

Commenting on earlier reports that Sequoia Fund exited their entire position, he said: They've sat down and they've seen and they've interviewed and they walked... The fact there they're selling tells everything, Left said. It's already a sinking ship ... With the Titanic going down you can at least get on a life boat and get out with what you can.

Shares of Valeant are up just 0.3 percent Wednesday.

You May Also Be Interested In

• Bloom Energy rejects short-seller report on finances and supply chain
• Boeing 737 Max 7 nears FAA certification after years of delays - WSJ
• Philippine Airlines to order 15 Boeing 787-10 and 9 Airbus A350-1000 jets - Reuters